Frontiers in Oncology (Aug 2022)
Corrigendum: Progression-free survival and time to progression as potential surrogate endpoints for overall survival in chemoradiotherapy trials in limited-stage small-cell lung cancer: A systematic review and meta-analysis
Abstract
No abstracts available.Keywords